Cybin Inc (CYBN) Reports Publication of Research Manuscript in the Journal of Medicinal Chemistry
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/13/2026
- S&P 500, Nasdaq decline as Iran tensions jolt sentiment; chip stocks fall
- SK Hynix’s record plunge drags down global chip stocks
- Oil gains over 4% as Trump says US reinstating Iran naval blockade
- Ditching streaming could boost Disney stock by 40%, Wells Fargo says
- AstraZeneca stock dips as HSBC downgrades stock on 'tough path ahead'
- Former emir of Qatar, Sheikh Hamad bin Khalifa Al Thani, dies at 74
- Goldman Sachs Upgrades NIO (NIO) to Buy
- BofA Securities on AppLovin: 'Current valuation appears reasonable'
- S&P 500, Nasdaq decline as Iran tensions jolt sentiment; chip stocks fall
- Japan has no plans to overhaul pension funds' asset allocation, sources say
Cybin Announces Publication of Research Manuscript in the Journal of Medicinal Chemistry
April 18, 2024 7:30 AM EDT- Publication explores structure-activity relationships (SAR) of a broad range of 2C-X analogs -
- Innovative research led to the discovery of CYB210010, a potent and long-acting serotonin 5-HT2 receptor agonist with favorable pharmacokinetic properties -
TORONTO--(BUSINESS WIRE)-- Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) (Cybin or the Company), a clinical-stage biopharmaceutical company committed... More
